Abstract:
In a circuit for suppressing short-lived noise phenomena in a digital audio signal, in particular during a temporary test reception of another transmitter, the audio signal is multiplied by a factor which, prior to the appearance of the noise phenomenon, is brought from a maximum value to a minimum value in accordance with a predetermined time function, and at the end of the noise phenomenon, is returned to a maximum value. The invention has special application to the Radio Data System defined by the European Broadcasting Union, and the testing of "Alternative Frequencies" in that system.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract:
The invention relates to a method for producing an injection valve for liquids, preferably an injection valve for injecting fuel into a combustion chamber of an internal combustion engine. The injection valve has a valve body, with a valve seat which is formed therein, and a valve needle which interacts with the valve seat in order to open and close at least one injection opening. The injection valve is produced by means of the following method steps: producing the valve body from steel, hardening the valve body, annealing a partial region of the valve body at an annealing temperature. The device for carrying out the method according to the invention has an inductive annealing generator which generates a suitable alternating current for operating a coil, in the magnetic field of which coil the valve body can be heated for annealing.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R9, Ar, Q1, Q2 and Q3 are each as defined below. The compounds of the formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of the formula I and to the use thereof as a medicament.
Abstract:
The present invention refers to human EGLN2 variants having at position 58 of the amino acid sequence a serine or a leucine and their use in the prevention or treatment of thromboembolic or coronary heart diseases, in particular stroke, prolonged reversible ischemic neurological deficit (PRIND), transitoric ischemic attack (TIA), myocardial infarction and/or early myocardial infarction.
Abstract:
The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
Abstract:
The present invention refers to the use of the Mst protein or a nucleotide sequence coding for the Mst protein for the treatment of a thromboembolic disorder and to a method of screening a modulator of the Mst protein or the nucleotide sequence coding for the Mst protein.
Abstract:
The present invention relates to LIMK-1, a LIMK-1-analogue or LIMK-1 ligand for the binding to GPIIb and/or activation or inhibition of GPIIb/IIIa downstream signaling, for the production of a medicament for the prevention or treatment of a thrombus formation or blood clotting disease, methods of screening a LIMK-1 analogue or a LIMK-1 ligand and a method for producing a medicament for the treatment of a thrombus formation or blood clotting disease.
Abstract:
The method for obtaining the quality signal includes multiplying a digital multiplex signal (MPX) by respective reference carrier signals mutually phase shifted by 90.degree. to each other, but otherwise equal, to form a pair of mixed signals (Imr1,Imr2); multiplying the mixed signals (Imr1, Imr2) by respective correction signals (G38c,G38s) to form a pair of corrected mixed signal (Ims1,Ims2); separately multiplying the digital multiplex signal (MPX) by each of two reference pilot signals mutually shifted in phase by 90.degree. relative to each other to form respective derived signals useful for obtaining said correction signals (G38c,G38s); adding said corrected mixed signals (Ims1,Ims2) to each other; multiplying said mixed signals (Imr1,Imr2) by the respective correction signals (G38s,G38c) to form a pair of product signals; subtracting these product signals from each other to form a subtraction result and low-pass filtering the subtraction result to obtain a low-pass-filtered resultant signal from which the quality signal is derived.
Abstract:
A circuit arrangement for deriving the signal indicating noise in a received stereo multiplex signal, wherein the stereo multiplex signal is present as a digital signal with a first sampling rate that is substantially higher than twice the upper limit of the useful frequency range of the stereo multiplex signal, and the received stereo multiplex signal is passed through a low-pass filter. The low-pass filtered signal and the received stereo multiplex signal are subjected to decimation to a second sampling rate, which is higher than twice the upper limit of the useful frequency range of the stereo multiplex signal. The two stereo multiplex signals with the second sampling rate are subtracted from one another.